The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity
Open Access
- 24 September 2019
- journal article
- review article
- Published by Elsevier in JACC: Cardiooncology
- Vol. 1 (1) , 105-113
Abstract
No abstract availableKeywords
Funding Information
- Division of Cancer Prevention, National Cancer Institute
- National Heart, Lung, and Blood Institute
- National Cancer Institute
This publication has 46 references indexed in Scilit:
- Recommendations for High-Priority Research on Cancer-Related Fatigue in Children and AdultsJNCI: Journal of the National Cancer Institute, 2013
- Multicenter, Randomized Controlled Trial of Yoga for Sleep Quality Among Cancer SurvivorsJournal of Clinical Oncology, 2013
- Response‐dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2012
- Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404)Blood, 2011
- Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort studyBreast Cancer Research, 2011
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway InhibitorsJNCI: Journal of the National Cancer Institute, 2010
- A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425Blood, 2009
- Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol S8897Journal of Clinical Oncology, 2008
- Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemiaBlood, 2006
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001